AgomAb Therapeutics Funding: $189M Raised, Series D (2024)
AgomAb Therapeutics is based in Ghent, Belgium. It has raised $189M in total funding. Latest round: Series D.
AgomAb Therapeutics funding overview
AgomAb Therapeutics is based in Ghent, Belgium. AgomAb Therapeutics has raised $189M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series D announced in October 2024. The round record for AgomAb Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Sanofi, Invus, Fidelity Management & Research Company, EQT Life Sciences, Canaan, Dawn Biopharma. 6 distinct backers are named across the disclosed rounds.
AgomAb Therapeutics at a glance
Total raised
$189M
Latest round
Series D
Latest round date
October 2024
Headquarters
Ghent, Belgium
Notable investors
Sanofi, Invus, Fidelity Management & Research Company, EQT Life Sciences, Canaan, Dawn Biopharma
Frequently asked about AgomAb Therapeutics funding
How much has AgomAb Therapeutics raised?
AgomAb Therapeutics has raised $189M in total disclosed funding across the rounds on record.
Who has invested in AgomAb Therapeutics?
Sanofi, Invus, Fidelity Management & Research Company, EQT Life Sciences, Canaan, Dawn Biopharma are named among the investors backing AgomAb Therapeutics.
What was the latest AgomAb Therapeutics funding round?
The most recent disclosed round is a Series D, announced in October 2024.
Where is AgomAb Therapeutics based?
AgomAb Therapeutics is based in Ghent, Belgium.
When did AgomAb Therapeutics last raise?
The last disclosed AgomAb Therapeutics round closed in October 2024 at Series D.
Round data for AgomAb Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Ghent and backer lists below.
